AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05683236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological and social support care
Description: Two nurses with psychological counselling qualifications in the team used the anxiety and depression scale to evaluate the psychological and emotional status of patients and referred to The Questionnaire Survey on Awareness of Palliative Care by the Department of Elderly Section of the union medical college hospital. The content mainly included the patient's medical history and general situation, the needs and awareness of patients and their families for palliative care, the choice of patients and their families for the final treatment plan, and the needs of families for grief counselling. Timely professional counselling and intervention were undertaken to alleviate the patient's adverse emotions.
Study NCT02252016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir + Elbasvir
Description: FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
Study NCT05683236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine nursing intervention
Description: The control group was given routine nursing intervention, strictly in accordance with a routine treatment process, monitoring the vital signs of patients, giving basic nursing, health education, diet guidance and so on.
Study NCT02252016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching grazoprevir + elbasvir FDC tablets taken once daily by mouth.
Study NCT01608646 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: S-1 plus oxaliplatin
Description: S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raven's SPM
Description: See Detailed Study Description.
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reading ability
Description: See Detailed Study Description.
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ishihara's tests for colour deficiency
Description: See Detailed Study Description.
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional questionnaire
Description: including questions about somatic disease, current medication, BMI, smoking habits, first menstruation, last menstruation's first day, days without active oral contraceptive pill during last month, claustrophobia, vision impairment.
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brown-ADD
Description: See Detailed Study Description.
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MFQ
Description: See Detailed Study Description.
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STAI-T
Description: See Detailed Study Description.
Study NCT03328273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: An ATP competitive, orally bioavailable inhibitor of the Serine/Threonine protein kinase Ataxia Telangiectasia and Rad3 related (ATR).
Study NCT03328273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: An experimental anti-cancer drug and Bruton's tyrosine kinase (BTK) inhibitor.
Study NCT01959945 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flublok® Quadrivalent Influenza Virus Vaccine
Description: Intramuscular (Relevant year formulation)
Study NCT01959945 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix Quadrivalent® Influenza Virus Vaccine
Description: Intramuscular (Relevant year formulation)
Study NCT01919463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal Compression
Description: Abdominal Compression is conducted by GI assistants during intubation process to facilitate the process. It can be conducted at different ares of the abdomen with different force.
Study NCT01919463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guidance of Magnetic Endoscopic Imaging (MEI) System
Description: Live image of MEI can show the form of the colonoscope inside the body. Live image is show to colonoscopist for facilitating the intubation process.
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BIS
Description: See Detailed Study Description.
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DAWBA
Description: See Detailed Study Description.
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STAI-S
Description: See Detailed Study Description.
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleepiness rating
Description: Acquired 6 times while in MRI-scanner. See Detailed Study Description.
Study NCT02662907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Barium Swallow
Description: Participants receive modified barium swallow at baseline and after 8 weeks of using the EMST device
Study NCT02662907 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Barium Swallow
Description: Participants receive modified barium swallow at baseline and after 8 weeks of using the EMST device
Study NCT02662907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.
Study NCT02662907 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.
Study NCT02662907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training (EMST) Device
Description: Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks.
Study NCT02662907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Manometer
Description: Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device.
Study NCT02662907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive Exams
Description: Participants given neurocognitive exams at baseline.
Study NCT02662907 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neurocognitive Exams
Description: Participants given neurocognitive exams at baseline.
Study NCT00931138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy (Aracytine + Daunorubicin)
Description: Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3
Study NCT02662907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Barium
Description: Participants receive barium prior to modified barium swallow at baseline and after 8 weeks of using the EMST device.
Study NCT02662907 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Barium
Description: Participants receive barium prior to modified barium swallow at baseline and after 8 weeks of using the EMST device.
Study NCT04471844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune®
Description: Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division.~In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.~In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.
Study NCT04471844 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optune®
Description: Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division.~In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.~In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression.
Study NCT00931138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy (Aracytine + Daunorubicin)
Description: Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3
Study NCT00931138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy (Aracytine + Daunorubicin)
Description: Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4
Study NCT01345643 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of hemoglobin level not less than 10g/dL
Description: The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.
Study NCT01345643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfusion trigger based on WCPTS
Description: Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
Study NCT04286386 — intervention group
Intervention type: OTHER
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV
Study NCT04286386 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Spectroscopic Imaging
Description: Undergo MRSI
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivation rating
Description: Acquired 6 times while in MRI-scanner. See Detailed Study Description.
Study NCT04286386 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical Procedure
Description: Undergo standard of care surgery
Study NCT01396928 — intervention group
Intervention type: PROCEDURE
Intervention: Colonic reservoir
Description: Type of reservoir to be performed
Study NCT02019563 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RCT Group
Description: After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and the pulp tissue removed. The canal will be irrigated with water and then filled with non-reinforced ZOE.
Study NCT02019563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MTA/FS pulpotomy Group
Description: After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and vital coronal pulp to a depth of 2mm below free gingival margin will be removed. A solution of ferric sulfate will be applied to the amputated pulp surface and then flushed with water. MTA paste is then used to cover over the exposed amputated pulp surface.
Study NCT02797873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FEFA2
Description: Assessing ability to recognise emotional face, performed at a computer at first visit. See Detailed Study Description.
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structural T1 MRI scan
Description: See Detailed Study Description and Outcome Measures.
Study NCT03124680 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Opioid free
Description: Peroperative opioid free anesthesia will be obtained via a combination of dexmedetomidine, ketamine, lidocaine and magnesium sulfate
Study NCT03124680 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: opioid group
Description: Opioid anesthesia will follow the current standard approach of our hospital.
Study NCT02348437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repair
Description: An on-going suture technique with minimum four stitches.
Study NCT02348437 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-repair
Description: The PQ muscle will be placed so it covers the volar plate. No suture.
Study NCT01877096 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: A brief motivational interviewing session
Study NCT01877096 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants will be asked to discuss the sources (e.g., the Internet) in which they receive information about their health. This group is designed to control for potential beneficial effects of meeting with an interventionist.
Study NCT01801384 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Voucher-based incentives
Study NCT01801384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voucher-based incentives
Study NCT00544492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: catheter for AV fistula cannulation
Description: catheters for buttonhole technique (blunt, bevel point), catheters for rope ladder technique (sharp, bevel point or sharp, cylindrical point)
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structural T2 MRI scan
Description: See Detailed Study Description.
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DTI MRI scan
Description: See Detailed Study Description and Outcome Measures.
Study NCT00544492 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: catheter for AV fistula cannulation
Description: catheters for buttonhole technique (blunt, bevel point), catheters for rope ladder technique (sharp, bevel point or sharp, cylindrical point)
Study NCT04572230 — intervention group
Intervention type: DEVICE
Intervention: Endovascular treatment of intracranial aneurysms using a flow-diverting stent
Description: The flow diverter brings about a reduction of blood flow to the aneurysm, which progresses over time into forming a stable thrombus within the aneurysm, as well as eventual aneurysm scarring and retraction. The flow diverter also acts as a scaffold for tissue growth across the neck of the aneurysm, which blocks the aneurysm from the artery blood flow.
Study NCT04072432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-3
Description: intravenous administration
Study NCT01402050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CERVIDIL (Dinoprostone)
Description: INDUCTION OF LABOR
Study NCT02797873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resting state MRI scan
Description: See Detailed Study Description and Outcome Measures.
Study NCT03079115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose Atorvastatin
Description: high-dose Atorvastatin (80 mg QD from 3 days before to 3 days after CAS, and thereafter 20mg QD until 30 days after CAS)
Study NCT03079115 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Conventional-dose Atorvastatin
Description: conventional-dose Atorvastatin(20 mg QD from 3 days before to 30 days after CAS).
Study NCT01868789 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Weightbearing CT
Study NCT01868789 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Weightbearing CT
Study NCT00811148 — intervention group
Intervention type: PROCEDURE
Intervention: Tissue Bank
Description: Collection of clinical data and tumor tissue.
Study NCT00832143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral Card with one-to-one counseling
Description: A Referral Card (Neonatal Well-Being Card) along with one-to-one counseling to mothers within 48 hours of institutional delivery
Study NCT01305356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augment® Injectable Bone Graft
Description: Implantation of up to 9cc of Augment® Injectable Bone Graft
Study NCT01305356 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous bone graft
Description: Implantation of up to 9cc of autologous bone graft
Study NCT05251064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: Standard suture wound closure device.
Study NCT05251064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clozex
Description: Interlaced adhesive wound closure device.
Study NCT05251064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zipline
Description: Adhesive wound closure device using zip-tie like strips.
Study NCT03348826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate 8.4% Solution for Injection
Description: 3 mL injection into line with up to 2 injections administered
Study NCT03348826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase Injectable Solution
Description: 2 mL injection into line with up to 2 injections administered
Study NCT02924675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 150mg daily in three doses during three weeks
Study NCT01402050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FOLEY BALLOON
Description: INDUCTION OF LABOR
Study NCT03834077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue flossing
Description: Electrotherapy (transcutaneous electrical nerve stimulation) and Ultrasound in addition to tissue flossing.
Study NCT03834077 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Conventional physiotherapy in addition to flossing without tension
Study NCT02804724 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03605641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL
Description: JUUL Virginia Tobacco
Study NCT03605641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VUSE Solo
Description: VUSE SOLO Original
Study NCT03605641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Cigarette
Description: Subject preferred conventional cigarette
Study NCT03223779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: Trifluridine stops DNA replication which may prevent the cancer cells from growing
Study NCT03223779 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon SBRT
Description: SBRT stands for Stereotactic Body Radiation Therapy. Radiation may help to kill the cancer cells while protecting your normal tissue cells
Study NCT01274143 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TeleCARE
Description: Personalized telephone-delivered cancer risk assessment.
Study NCT03287349 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Two 12.5 mL blood draws
Study NCT03287349 — intervention group
Intervention type: OTHER
Intervention: Photograph
Description: Photograph of severe reaction, will be anonymized
Study NCT01274143 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pamphlet intervention
Description: Mailed pamphlet about familial colorectal cancer risk and screening.
Study NCT00582244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT and relaxation
Description: Group A: CBT and relaxation.
Study NCT00582244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Group B: Physical exercise program.
Study NCT00582244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT and physical activity
Description: Group AB: Combined CBT and exercise program. Women assigned to Group AB will undergo the CBT and exercise elements of the program concurrently. To as great an extent as possible, the on-site CBT and in-clinic exercise training sessions will be scheduled on the same day.
Study NCT00582244 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control group
Description: Waiting list control group
Study NCT03287349 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Autoimmune testing
Description: Autoimmune testing in patients without prior testing
Study NCT03586609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV
Study NCT03586609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV
Study NCT01322633 — intervention group
Intervention type: OTHER
Intervention: Does not apply
Description: This is a non-interventional study, therefore the intervention type / name do not apply.
Study NCT03921918 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Breast Pump
Description: Hydraulic Breast pump
Study NCT03209505 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Acuvue Oasys
Description: FDA approved contact lens, fit for daily wear
Study NCT03209505 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Air Optix Night & Day Aqua
Description: FDA approved contact lens, fit for daily wear
Study NCT00265226 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra-dermal administration of Mycobacterium w
Description: Mw Vaccine is given as oral suspension. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
Study NCT00265226 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intra-dermal administration of Mycobacterium w
Description: Mw Vaccine is given as oral suspension. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks